This section of the Psoriasis Academy will provide an overview of all aspects of disease management, including its burden on patients and healthcare resources, unmet needs that have been identified, and the role of different assessment tools in classifying severity and determining treatment response.
Moderate to severe plaque psoriasis (with or without psoriatic arthritis) places significant social, physical and emotional burden on patients’ lives. (Pariser et al., 2016; Korman et al., 2016). Despite treatment, many patients with psoriasis continue to experience clinical symptoms and impaired functioning (Schaefer et al., 2015).
Alongside the significant impact on patient’s quality of life, psoriasis also impacts utilisation of healthcare resources, associated costs and work productivity (Pariser et al., 2016; Korman et al., 2016).
Patient-oriented care requires that therapy is aligned with the patients’ needs/treatment goals. The German Psoriasis registry (PsoBest) has demonstrated that the majority of patients with moderate to severe psoriasis aspire to a normal everyday life with a low treatment burden (Blome et al., 2016).
There are several ways of assessing psoriasis. According to guidelines the most established parameter in measuring the severity of skin symptoms in psoriasis is the Psoriasis Area and Severity Index (PASI), which represents a necessary first step in selecting a treatment strategy and provides valuable feedback in measuring long term response to treatment. (Pathirana et al., 2009). A PASI 75 response is now widely accepted as a clinically meaningful improvement.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Almirall S.A, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.